Last update: July 31, 2018

Périndopril

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

Perindopril and its active metabolite perindoprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension and heart failure.
Oral administration every 12-24 hours.

It is excreted in breastmilk in clinically insignificant amounts (Anderson 2018, Lwin 2017).

Until there is more information about this drug in relation to breastfeeding, safer known alternatives are preferable.

Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015).

The protective role of breastfeeding against maternal hypertension has been proven (Park 2018).

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Périndopril is Perindopril in French.

Is written in other languages:

Périndopril is also known as

Group

Périndopril belongs to this group or family:

Tradenames

Main tradenames from several countries containing Périndopril in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 65 - 75 %
Molecular weight 369 daltons
Protein Binding 10 - 20 %
VD 0,22 l/Kg
pKa 3,79 -
Tmax 3 - 4 hours
T1/2 30 hours
M/P ratio 0,22 -

References

  1. Park S, Choi NK. Breastfeeding and Maternal Hypertension. Am J Hypertens. 2018 Abstract
  2. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  3. Lwin EMP, Gerber C, Song Y, Leggett C, Ritchie U, Turner S, Garg S. A new LC-MS/MS bioanalytical method for perindopril and perindoprilat in human plasma and milk. Anal Bioanal Chem. 2017 Abstract
  4. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Abstract
  5. AEMPS. Perindopril Ficha técnica. 2012 Full text (in our servers)
  6. FDA. Perindopril. Drug Summary. 2011 Full text (in our servers)

Total visits

359

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child's Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM